The US Food and Drug Administration (FDA) has approved Incyte’s (Nasdaq: INCY) Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination ...

The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec for the treatment of ...

Neurocrine Biosciences, the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help ...

Chinese AI drug developer METiS Pharmaceuticals is preparing for a Hong Kong initial public offering that could raise up to $200 million, highlighting the ongoing surge of investment in artificial ...

Irish contract research organization ICON (Nasdaq: ICON) has retained its position as the most active CRO worldwide in the ...

Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a ...

US clinical-stage biotech Therini Bio yesterday revealed that it raised $39 million in a Series A extension financing, which ...

New York-based Pathos AI, a biotech company applying artificial intelligence (AI) to drug development, has announced a $365 ...

The US Food and Drug Administration’s (FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that ...

A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

Shares of Travere Therapeutics (Nasdaq: TVTX) fell 15.8% to $21.15 in after-hours trading, as the company revealed that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug ...

New Jersey, USA-based cancer giant Merck & Co (NYSE: MRK) has announced it will unveil a comprehensive slate of new research ...